

PeriGen & WatchChild – FAQ

PeriGen and WatchChild have joined forces to create the most comprehensive perinatal patient safety solution. PeriGen brings its industry-leading clinical decision support tools, anchored by the only NICHD-validated fetal heart rate pattern recognition and interpretation platform, while WatchChild provides a world-class enterprise architecture and unique access to maternal/fetal data. .

When the PeriGen and WatchChild teams first discussed a possible merger, it became crystal clear that both had a passion for providing innovative solutions to their customers. Now, those customers will be able to realize the “best-of-the-best” from both organizations. Our combined customer base of nearly 300 hospitals and health systems, spanning academic centers to critical access hospitals, will not only benefit from the current solutions and services that PeriGen and WatchChild offer, but will also play a major role in shaping future solutions.

Q What will the company be called?

A *The merger of PeriGen and WatchChild will be called PeriGen.*

Q Why did PeriGen and WatchChild merge?

A *To bring two complimentary visions together with similar customer bases. Both organizations have some of the nation's most prestigious health systems as their current customers. The combined entity will enable us to bring new, advanced patient safety solutions more rapidly to the broader perinatal market.*

Q Where will the company be located?

A *The company will establish its corporate headquarters in Cary, NC.*

Q Who will be the management team going forward?

A *The company will be led by Matt Sappern, CEO; John Coats, CFO; Denise Queffelec, SVP Professional Services; Brian Bishop, Chief Product Officer; and Chip Long, SVP Growth & Marketing.*

Q Will my current system change in some way?

A Customers will continue using their current systems with full contracted support. Going forward, customers will have access to new features and incremental clinical tools

Q How will the merger influence my upcoming implementation?

A *All scheduled implementation and upgrade activities will continue as planned.*

Q How will the merger influence my support?

A *Your current support will continue and, over time be strengthened with the combination of the two organizations. Continue accessing customer support as you do presently.*

Q What about the upgrades and enhancements currently being worked on by PeriGen/WatchChild?

A *Both PeriGen and WatchChild have active product enhancement roadmaps and will continue to enhance the existing applications, as well as exploring collaborative development.*

Q How soon will PeriCALM artificial intelligence and Clinical Decision Support features be available for my WatchChild system?

A *The teams will begin working on a development timeline immediately, with the anticipation of being able to implement these tools with WatchChild customers within 120-180 days.*

Q Will I have to change to PeriCALM from WatchChild?

A *No. PeriGen will continue to support both our PeriCALM and WatchChild customers.*

Q Will I have to change to WatchChild from PeriCALM?

A *No. PeriGen will continue to support both our PeriCALM and WatchChild customers.*

Q Who do I call for support or upgrades or questions?

A *Access to customer support will not change. Both PeriGen and WatchChild Customers will continue to receive support as they have been.*

Q Will features that I love about my system go away?

A *No. Both PeriGen and WatchChild customers will continue to enjoy the features that they currently use. PeriGen will continue to focus on enhancements for customers using both solutions.*

Q Where do I go to find out more information about PeriGen and WatchChild and their respective solutions:

A Currently, information on:

- PeriGen's PeriCALM solutions are available at www.perigen.com.
- Information on WatchChild can be found at www.perigen.com/about-WatchChild
- Additional information on the acquisition of WatchChild by PeriGen can be found at www.perigen.com/perigen-watchchild-join-forces/